AACR 101st Annual Meeting 2010: New Concepts in Organ Site Research Sessions

Bridging the Gap: Moving Laboratory Discoveries into Clinical Trials

Chairperson: Michael A. Dyer, St. Jude Children’s Research Hospital, Memphis, TN

• Development of “Achilles heel” screening in rhabdomyosarcoma identifies novel therapeutic targets
  Lee J. Helman, National Cancer Institute, Bethesda, MD
• Understanding the behavior of pediatric brain tumors: A developmental perspective
  Richard J. Gilbertson, St. Jude Children’s Research Hospital, Memphis, TN
• Identification and exploitation of molecular targets in neuroblastoma
  John M. Maris, Children’s Hospital of Philadelphia, Philadelphia, PA
• Local delivery of nutlin-3a in preclinical models of retinoblastoma
  Michael A. Dyer

From Prostate Cancer Susceptibility Gene Identification to Personalized Medicine

Co-Chairpersons: Johann S. de Bono, Institute of Cancer Research, Sutton, United Kingdom, and Arul M. Chinnaiyan, University of Michigan, Ann Arbor, MI

• The role of gene fusions in prostate cancer
  Arul M. Chinnaiyan
• Genetic predisposition to prostate cancer and targeted screening and treatment
  Rosalind A. Eeles, Institute of Cancer Research, Sutton, United Kingdom
• Prostate cancer epigenomics: Application to personalized medicine
  Vasan Yegnasubramanian, Johns Hopkins University, Baltimore, MD
• Therapeutic implications of prostate cancer genetic studies
  Johann S. de Bono

Personalized Therapy of Advanced Non-Small Cell Lung Cancer

Co-Chairpersons: Roy S. Herbst, UT M. D. Anderson Cancer Center, Houston, TX, and Thomas J. Lynch, Yale Cancer Center, New Haven, CT

• Introduction: Molecular origins of lung cancer
  Roy S. Herbst
• Genomic profiling of NSCLC: Target and pathway identification
  Anil Potti, Duke University Medical Center, Durham, NC
• Lung cancer pathology: The M. D. Anderson BATTLE experience
  Ignacio I. Wistuba, UT M.D. Anderson Cancer Center, Houston, TX
• EGFR gene mutations in clinical practice
  Thomas J. Lynch
• Additional speaker to be announced

Progress in Pancreatic Cancer, 2010

Co-Chairpersons: David A. Tuveson, Cancer Research UK, Cambridge, United Kingdom, and Mark S. Talamonti, NorthShore University Health System, Evanston, IL

• Unraveling pancreatic cancer susceptibility: From genomes to patient care
  Alison P. Klein, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD
• Pancreatic cancer genome project
  Thomas J. Hudson, Ontario Institute for Cancer Research, Toronto, ON, Canada
• The role of K-Ras oncogenes, senescence, and inflammation in the development of PDAC
  Mariano Barbacid, Spanish National Cancer Research Center (CNIO), Madrid, Spain
• Epithelium and stroma: Double trouble
  Daniel D. Von Hoff, Translational Genomics Research Institute, Phoenix, AZ

Bladder Cancer: Prediction of Prognosis and Therapeutic Response in Patients with High-Risk Disease

Chairperson: Dan Theodorescu, University of Virginia, Charlottesville, VA

• A phase 1 study with intravesical Ad-IFNa/Syn3 for superficial bladder cancer
  William F. Benedict, UT M. D. Anderson Cancer Center, Houston, TX
• Molecular pathways of progression and response in bladder cancer: New approaches based on novel technologies
  Richard J. Cote, University of Miami Miller School of Medicine, Miami, FL
• microRNAs in bladder cancer: Data from parallel miR screenings of clinical specimens and their potential regulatory effects
  Torben F. Ørntoft, Aarhus University Hospital, Skejby, Denmark
• A novel approach to the discovery of genetic determinants of therapeutic response
  Dan Theodorescu
• Molecular pathways of urothelial tumorigenesis based on genetically engineered models
  Xue-Ru Wu, New York University School of Medicine, New York, NY

Medulloblastoma: Genetics and Genomics

Co-Chairpersons: Martine F. Roussel, St. Jude Children’s Research Hospital, Memphis, TN, and William A. Weiss, University of California, San Francisco, CA

• Interactions between proliferation-controlling pathways in the developing cerebellum and medulloblastoma
  Anna M. Kenney, Memorial Sloan-Kettering Cancer Center, New York, NY
• Original sin: What normal progenitors can teach us about the biology of medulloblastoma
  Robert J. Wechsler-Reya, Duke University Medical Center, Durham, NC
• Recent advances in the genetics of medulloblastomas
  Michael D. Taylor, University of Toronto Hospital for Sick Children, Toronto, ON, Canada
• Hedgehog signaling in childhood tumors of the hindbrain
  Philip A. Beachy, Stanford University, Stanford, CA

New Concepts in Lymphoid Malignancies: Molecular Determinants of Oncogenesis and Clinical Behavior

Co-Chairpersons: Andrew C. Rawstron, Leeds General Infirmary, Leeds, United Kingdom, and Anthony G. Letai, Dana-Farber Cancer Institute, Boston, MA

• Insights into oncogenesis and disease progression from premalignant lymphoid disorders
  Andrew C. Rawstron
• Measuring and exploiting the predisposition to apoptosis in lymphoid malignancies
  Anthony G. Letai
• Understanding inherited susceptibility to ALL and CLL
  Richard Houlston, Institute of Cancer Research, Belmont, Sutton, United Kingdom
• Oncogenomics of B-cell malignancies
  Laura Pasqualucci, Columbia University Medical Center, New York, NY

Advances in Skin Cancer: New Treatment, New Virus, New Mouse Models

Chairperson: Yuan Chang, University of Pittsburgh Cancer Institute, Pittsburgh, PA

• Title to be announced
  Thomas S. Kupper, Harvard Institutes of Medicine, Boston, MA
• Modeling nonmelanoma skin cancers in mice
  Marcus W. Bosenberg, Yale University School of Medicine, New Haven, CT
• Merkel cell polyomavirus: A new human tumor virus
  Yuan Chang
• Title to be announced
  Glen J. Weiss, Translational Genomics Research Institute, Scottsdale, AZ

Recent Advances in Ovarian Cancer Research

Co-Chairpersons: Shelley S. Tworoger, Brigham and Women’s Hospital, Boston, MA, and Christopher P. Crum, Brigham and Women’s Hospital, Boston, MA

• Newly identified dietary and other epidemiologic risk factors in ovarian cancer
  Alicja Wolk, National Institute of Environmental Medicine, Stockholm, Sweden
• Molecular phenotypes of ovarian cancer: What have we learned?
  David D.L. Bowtell, Peter MacCallum Cancer Center, East Melbourne, Australia
• New molecular markers of ovarian cancer risk
  Martin Widschwendter, Institute for Women’s Health, University College London, London, United Kingdom
• Targeted therapy in ovarian cancer
  Elise C. Kohn, National Cancer Institute, Bethesda, MD

Developing a Rational Approach to Luminal B Breast Cancer

Chairperson: Monica Morrow, Memorial Sloan-Kettering Cancer Center, New York, NY

• Molecular classification of luminal breast cancers
  Charles M. Perou, The University of North Carolina, Chapel Hill, NC
• Current clinical approach to luminal B breast cancer
  Clifford A. Hudis, Memorial Sloan-Kettering Cancer Center, New York, NY
• Molecular effects of estrogen deprivation from luminal tumors
  Mitchell Dowsett, Royal Marsden NHS Trust, London, United Kingdom
• Novel approaches to luminal B breast cancer
  Philippe Bedard, Princess Margaret Hospital, Toronto, ON, Canada

Mechanistic Approach to Targeted Therapy for Advanced Kidney Cancer

Chairperson: Robert J. Motzer, Memorial Hospital, New York, NY

• Clinical overview of targeted drugs for metastatic renal cell carcinoma
  Robert J. Motzer
• Genetic basis of kidney cancer: Opportunity for diseasespecific targeted therapy
  W. Marston Linehan, National Cancer Institute, Bethesda, MD
• Molecularly defining subgroups of renal cell carcinoma
  W. Kimryn Rathmell, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC
• Elucidating the two subtypes of VHL-deficient clear cell renal cancer
  Katherine L. Nathanson, University of Pennsylvania School of Medicine, Philadelphia, PA

Molecularly Targeted Strategies for Melanoma

Co-Chairpersons: Keith T. Flaherty, Massachusetts General Hospital, Boston, MA, and Marcus W. Bosenberg, Yale University School of Medicine, New Haven, CT

• Preclinical models for the evaluation of molecularly targeted melanoma therapies
  Marcus W. Bosenberg
• Seven years to validate BRAF as a therapeutic target in patients
  Keith T. Flaherty
• Melanoma drug/target discovery through the mutational analysis of the melanoma genome
  Yardena Samuels, National Human Genome Research Institute, Bethesda, MD
• Cell responses to BRAF inhibitors in vitro and in vivo
  Richard M. Marais, Institute of Cancer Research, London, United Kingdom

Novel Approaches to Small Cell Lung Cancer

Chairperson: Charles M. Rudin, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD

• Genomic alterations and focal adhesion pathway in small cell lung cancer
  Pierre P. Massion, Vanderbilt University Medical Center, Nashville, TN
• Hedgehog signaling in small cell carcinogenesis and treatment
  Craig D. Peacock, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD
• The unmet potential for immunotherapy in small cell lung cancer
  Lee M. Krug, Memorial Sloan-Kettering Cancer Center, New York, NY
• Targeting Bcl-2 and apoptotic resistance in small cell lung cancer
  Charles M. Rudin

Basic and Translational Advances in Gastric Cancer

Co-Chairpersons: Patrick B. Tan, Duke-NUS Graduate Medical School, Singapore, and Toshikazu Ushijima, National Cancer Center Research Institute, Tokyo, Japan

• Helicobacter pylori and molecular pathogenesis
  Masanori Hatakeyama, Hokkaido University, Sapporo, Japan
• Induction of epigenetic alterations by H. pylori-induced inflammation
  Toshikazu Ushijima
• Linking inflammation and stomach cancer in mouse models
  Timothy C. Wang, Columbia University Medical Center, New York, NY
• Genomic strategies for dissecting gastric cancer heterogeneity
  Patrick B. Tan

Malignant Gliomas: Advances and Challenges in Research and Therapy

Co-Chairpersons: Francis Ali-Osman, Duke University Comprehensive Cancer Center, Durham, NC, and Mitchel S. Berger, University of California, San Francisco, CA

• Tumor stem cells in gliomas: Concepts, controversies, and opportunities
  Rolf Bjerkvig, University of Bergen, Bergen, Norway
• Glioma epigenetics and the epigenome project: Implications for glioma biology and therapy
  Joseph F. Costello, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
• Advances, challenges, and opportunities of immunotherapy and vaccine therapy of malignant gliomas
  Darell D. Bigner, Duke University Medical Center, Durham, NC
• Targeted and chemotherapy of malignant gliomas: Advances, challenges, and where we go from here
  Roger Stupp, University Hospital (CHUV), Lausanne, Switzerland
• Unraveling the genetics of human gliomas: Advances, opportunities, and challenges
  Markus Bredel, Northwestern University, Chicago, IL

New Insights into the Myelodysplastic Syndromes

Co-Chairpersons: Kevin M. Shannon, University of California, San Francisco, CA, and Stephen D. Nimer, Memorial Sloan-Kettering Cancer Center, New York, NY

• Anatomy of 5q deletions and candidate genes
  Michelle M. LeBeau, University of Chicago, Chicago, IL
• Using chromosome engineering to model 5q deletions in the mouse
  Andrew McKenzie, Medical Research Council Laboratory of Molecular Biology, Cambridge, United Kingdom
• MDS and aberrant ribosome function
  Benjamin Ebert, Brigham and Women’s Hospital, Boston, MA
• MDS stem cells: Do they exist and how can we target them?
  Stephen D. Nimer

The Biology of Prostate Cancer

Chairperson: Philip W. Kantoff, Dana-Farber Cancer Institute, Boston, MA

• PTEN signaling pathway and prostate cancer stem cells
  Hong Wu, UCLA David Geffen School of Medicine, Los Angeles, CA
• The roles of inflammation and MYC in prostate cancer
  Angelo M. De Marzo, Johns Hopkins University School of Medicine, Baltimore, MD
• ETS gene fusions in prostate cancer: Bench to bedside
  Scott A. Tomlins, University of Michigan Medical School, Ann Arbor, MI
• Androgen signaling in advanced prostate cancer
  Philip W. Kantoff

Melanoma: Genetics of Predisposition, Initiation, and Progression

Chairperson: Boris C. Bastian, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

• Functionalizing the cancer genome
  Lynda Chin, Dana-Farber Cancer Institute, Boston, MA
• G-protein mutations in uveal melanoma and intradermal melanocytic proliferations
  Boris C. Bastian
• Genes controlling UV and pigmentation responses in skin
  David E. Fisher, Harvard Medical School, Boston, MA
• Title to be announced
  Marianne Berwick, University of New Mexico, Albuquerque, NM

New Concepts in Colon Cancer Research

Co-Chairpersons: Sanford D. Markowitz, Case Western Reserve University, Cleveland, OH, and Lee M. Ellis, UT M. D. Anderson Cancer Center, Houston, TX

• Genetic approaches to early detection and to prevention of colon neoplasms
  Sanford D. Markowitz
• Prognostic and predictive factors for colorectal cancer
  Monica M. Bertagnolli, Brigham and Women’s Hospital, Boston, MA
• Glucose-deprived environment can drive the development of K-Ras pathway mutations in tumor cells
  Nickolas Papadopoulos, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD
• CpG island methylator phenotype: An update
  Jean-Pierre J. Issa, UT M. D. Anderson Cancer Center, Houston, TX
• Inflammation and colon cancer: Interweaving microRNA and p53 pathways
  Curtis C. Harris, National Cancer Institute, Bethesda, MD

Sarcoma Genomics: Translating New Discoveries into Therapeutic Targets

Chairperson: Samuel Singer, Memorial Sloan-Kettering Cancer Center, New York, NY

• Sarcoma genomic alterations define new targets for therapy
  Samuel Singer
• Genetic and epigenetic determinants of sarcoma with massively parallel sequencing
  Barry S. Taylor, Memorial Sloan-Kettering Cancer Center, New York, NY
• Functional screening for mediators of sarcoma invasion and metastasis
  Poul H. B. Sorensen, University of British Columbia, Vancouver, BC, Canada
• Targeting sarcoma oncogenes with small molecule proteinprotein interaction inhibitors
  Jeffrey A. Toretsky, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC

Translational Initiatives in Mesothelioma

Chairperson: Harvey Ira Pass, New York University Medical Center, New York, NY

• New developments in the mechanisms of asbestos carcinogenesis
  Haining Yang, Cancer Research Center of Hawaii, Honolulu, HI
• Exploiting emerging biology for the treatment of malignant mesothelioma
  David M. Jablons, University of California, San Francisco, CA
• Title to be announced
  Anton J. M. Berns, Netherlands Cancer Institute, Amsterdam, The Netherlands
• Novel platforms for the early detection and prognostication of mesothelioma
  Harvey Ira Pass

Head and Neck Cancer: New Trends in Genetics, Biology, and Treatment

Chairperson: Jennifer R. Grandis, University of Pittsburgh School of Medicine, Pittsburgh, PA

• Cross-talk between endothelium and tumor cells in head and neck cancer
  Jacques E. Nör, University of Michigan, Ann Arbor, MI
• Strategies to overcome resistance to EGFR inhibitors
  Paul M. Harari, University of Wisconsin Hospital, Madison, WI
• The Akt-mTOR signaling network and head and neck cancer: Novel molecular targeted therapies
  J. Silvio Gutkind, National Institutes of Health, Bethesda, MD
• Epigenetic alterations in head and neck squamous cell carcinoma
  Karl T. Kelsey, Brown University, Providence, RI

Lung Cancer: Risk, Genetics, and Addiction

Co-Chairpersons: Caryn Lerman, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, and Christopher I. Amos, UT M. D. Anderson Cancer Center, Houston, TX

• Untangling genetic contributions to lung cancer susceptibility and cigarette smoking
  Christopher I. Amos
• The genetics of variable nicotine metabolism and implications for targeted therapy for nicotine addiction
  Caryn Lerman
• Genome-wide and candidate gene associations with smoking behaviors
  Neil E. Caporaso, National Cancer Institute, Bethesda, MD
• Understanding effects of nicotinic receptors on dependence and disease through mouse models
  Ming You, Washington University Siteman Cancer Center, St. Louis, MO

New Concepts in Bone Metastasis

Co-Chairpersons: Yves A. DeClerck, USC/Children’s Hospital, Los Angeles, CA, and Robin L. Anderson, Peter MacCallum Cancer Center, Melbourne, Australia

• Perspectives
  Robin L. Anderson
• Tumor-stroma interactions in breast cancer bone metastasis: Novel insights from functional genomics
  Yibin Kang, Princeton University, Princeton, NJ
• The role of Wnts in the bone metastatic microenvironment
  Evan T. Keller, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI
• TGFβ-BMP interactions in bone metastasis formation: Potential therapeutic implications
  Gabri van der Pluijm, Leiden University Medical Center, Leiden, The Netherlands
• Testing new targeted therapies in bone metastasis
  Katherine N. Weilbaecher, Washington University School of Medicine, St. Louis, MO
• Panel Discussion
  Yves A. DeClerck, Moderator

Regulation of Normal and Transformed Breast Cancer Stem Cell Behavior

Co-Chairpersons: Max S. Wicha, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, and Connie J. Eaves, BC Cancer Agency, Vancouver, BC, Canada

• Properties of normal breast stem cells
  Connie J. Eaves
• Regulation of self-renewing properties of mammary cancer stem cells
  Pier Giuseppe Pelicci, European Institute of Oncology, Milan, Italy
• Genomic heterogeneity of breast cancer
  Samuel Aparicio, BC Cancer Agency, Vancouver, BC, Canada
• Regulation of breast cancer stem cells by the microenviornment
  Max S. Wicha